Share on StockTwits

BioCryst Pharmaceuticals (NASDAQ:BCRX) CFO Thomas R. Staab II unloaded 10,000 shares of the stock in a transaction dated Wednesday, August 27th. The shares were sold at an average price of $13.58, for a total transaction of $135,800.00. Following the sale, the chief financial officer now directly owns 162,942 shares in the company, valued at approximately $2,212,752. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

BCRX has been the subject of a number of recent research reports. Analysts at JPMorgan Chase & Co. initiated coverage on shares of BioCryst Pharmaceuticals in a research note on Friday, August 8th. They set an “overweight” rating and a $20.00 price target on the stock. Analysts at Wells Fargo & Co. upgraded shares of BioCryst Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Monday, June 23rd. They now have a $17.00 price target on the stock, down previously from $19.00. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $18.33.

BioCryst Pharmaceuticals (NASDAQ:BCRX) traded up 2.69% on Friday, hitting $13.5651. 872,864 shares of the company’s stock traded hands. BioCryst Pharmaceuticals has a one year low of $4.55 and a one year high of $14.62. The stock’s 50-day moving average is $12.63 and its 200-day moving average is $10.93. The company’s market cap is $973.4 million.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.04. The company had revenue of $1.50 million for the quarter, compared to the consensus estimate of $2.32 million. During the same quarter in the prior year, the company posted ($0.23) earnings per share. The company’s quarterly revenue was up 79.3% on a year-over-year basis. On average, analysts predict that BioCryst Pharmaceuticals will post $-0.83 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX) is a biotechnology company.

Receive News & Ratings for BioCryst Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.